HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited has reported a substantial growth in its 2024 interim financial results, with oncology product revenue increasing by 59% to $168.7 million in the first half of the year and a strong US market launch of FRUZAQLA® generating $130.5 million in sales. The company boasts a healthy cash balance of $802.5 million, supporting continued investment in R&D and commercial efficiency. With several new drug applications underway and key late-stage trials initiated, HUTCHMED is strengthening its global presence and anticipates further revenue growth and potential new drug approvals.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
